ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1799

Circulating Vascular Adhesion Protein-1 Level Predicts Risk of Cardiovascular Events and Mortality in Hemodialysis Patients

Session Information

Category: Hypertension and CVD

  • 1402 Hypertension and CVD: Clinical, Outcomes, and Trials

Authors

  • Kim, Dae Kyu, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Lee, Yu ho, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
  • Yoon, Soo-Young, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Kim, Jongho, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Kim, Jin sug, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Kim, Yang gyun, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Lee, So-young, CHA Bundang Medical Center, Seongnam, Gyeonggi-do, Korea (the Republic of)
  • Ahn, Shin-Young, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Kang, Shinyeong, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Lee, Dong-Young, Korea Veterans Health Service, Seoul, Korea (the Republic of)
  • Jeong, Kyung hwan, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Moon, Ju young, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Hwang, Hyeon Seok, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
  • Lee, Sangho, Kyung Hee University Medical Center, Seoul, Korea (the Republic of)
Background

Vascular adhesion protein-1 (VAP-1) is an oxidative enzyme of primary amines that facilitates the transmigration of inflammatory cells. The oxidative and inflammatory effects of VAP-1 are prominently increased in pathological conditions such as metabolic, atherosclerotic, and cardiac diseases. However, the clinical significance of circulating VAP-1 levels in hemodialysis (HD) patients is unclear.

Methods

A total of 434 HD patients were prospectively enrolled between June 2016 and April 2019 as part of a prospective multicenter cohort study. Plasma VAP-1 levels were measured at the time of study data entry, and the primary endpoint was defined as a composite of cardiovascular (CV) events and cardiac events.

Results

Circulating VAP-1 levels were positively correlated with plasma levels of cardiac remodeling markers, including brain natriuretic peptides, galectin-3, and matrix metalloproteinase-2. Multivariate logistic regression analysis revealed that patients with higher circulating VAP-1 levels were more likely to have left ventricular (LV) diastolic dysfunction (odds ratio, 1.40; 95% confidence interval [CI], 1.04–1.88). The cumulative event rate of the composite of CV events was significantly greater in VAP-1 tertile 3 than in VAP-1 tertiles 1 and 2 (P = 0.009). Patients with VAP-1 levels in tertile 3 were also associated with an increased cumulative event rate of cardiac events (P = 0.015). The VAP-1 tertile 3 was associated with a 2.06-fold higher risk of the composite of CV events (95% CI, 1.10–3.85) and 2.06-fold higher risk of cardiac events (95% CI, 1.03–4.12) after adjustment for multiple variables.

Conclusion

Plasma VAP-1 levels had the positive relationship with circulating levels of cardiac pathology markers and LV diastolic dysfunction. Higher VAP-1 levels were also associated with an increased risk of incident CV events and cardiac events in HD patients. Our results indicate that VAP-1 help clinicians identify those at high risk of CV events